Smith & Nephew plc

06/21/2022 | Press release | Distributed by Public on 06/21/2022 04:04

Current Report by Foreign Issuer (Form 6-K)

a1958p
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
June 20, 2022
Commission File Number 001-14978
SMITH & NEPHEW plc
(Registrant's name)
Building 5, Croxley Park,
Hatters Lane, Watford, Hertfordshire, WD18 8YE,
England
(Address of registrant's principal executive offices)
[Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.]
Form 20-F X Form 40-F
--- ---
[Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1).]
Yes No X
--- ---
[Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7).]
Yes No X
--- ---
[Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing information to the
Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of
1934.]
Yes No X
--- ---
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b) : 82- n/a.
20 June 2022
Smith+Nephew announces new Senior Independent Director
Smith & Nephew plc (LSE:SN, NYSE:SNN) announces that Robin Freestonehas decided tostep down as Senior Independent Director and as a Non-Executive Director of Smith & Nephew plc with effect from 30 September 2022. Marc Owen, Non-Executive Director, will be appointed as Senior Independent Director with effect from the same date.
Mr Freestone was appointed as a Non-Executive Director in September 2015 and subsequently appointed as Senior Independent Director in April 2019. Mr Owen was appointed as a Non-Executive Director in October 2017. In addition to his appointment as Senior Independent Director, Mr Owen will continue in his role as Chair of the Compliance & Culture Committee and as a member of the Audit Committee and Nomination & Governance Committee. He will take over from Mr Freestone in leading the search for a new Chair of the company.
The Board would like to thank Mr Freestone for his commitment and contribution to the Board and the Company and to congratulate Mr Owen on his new appointment.
Enquiries
Investors
Andrew Swift
+44 (0) 1923 477433
Smith+Nephew
Media
Charles Reynolds
+44 (0) 1923 477314
Smith+Nephew
Susan Gilchrist / Ayesha Bharmal
+44 (0) 20 7404 5959
Brunswick
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'.Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visitwww.smith-nephew.com and follow us on Twitter, LinkedIn,Instagram or Facebook.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Smith & Nephew Plc
(Registrant)
Date: June 20, 2022
By: /s/ Helen Barraclough
-----------------
Helen Barraclough
Company Secretary